March 13, 2020 / 9:08 PM / 21 days ago

BRIEF-Aimmune Announces New Palforzia Data After 18 And 24 Months Of Treatment

March 13 (Reuters) - Aimmune Therapeutics Inc:

* AIMMUNE ANNOUNCES NEW PALFORZIA™ DATA SUGGESTING INCREASED DESENSITIZATION, IMPROVED TOLERABILITY AND CONTINUED IMMUNOMODULATION AFTER 18 AND 24 MONTHS OF TREATMENT

* AIMMUNE THERAPEUTICS - SURVEY RESULTS REINFORCE IMMUNOTHERAPY PRACTICE PATTERNS FOR FOOD ALLERGY IN REAL-WORLD SETTING

* AIMMUNE THERAPEUTICS - ANALYSIS FROM ARC004, OPEN-LABEL FOLLOW-ON TRIAL TO 52-WEEK PALISADE TRIAL, SHOWED THAT PATIENTS TOLERATED MORE PEANUT PROTEIN

* AIMMUNE THERAPEUTICS - DIFFERENCE IN PRIMARY ENDPOINT BETWEEN PALFORZIA AND PLACEBO WAS 63.2% AND IN ALL SUBGROUPS DIFFERENCE EXCEEDED 55% Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below